Pancreatic & Breast Cancer Survival Just Got A Lot Better | New Study Results
HealthDay Interviews Dr. Julie Gralow, Chief Medical Officer and EVP of ASCO about the RASolute 302 Trial of daraxonrasib, a RAS inhibitor that was shown to dramatically improve overall survival in patients with metastatic pancretic cancer -- and Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, about biomarker findings from the ASCENT-04 study on Triple-Negative Breast Cancer. https://www.healthday.com/med-meeting... I'm Doctor Julie Gralow. I'm ASCO's chief medical officer and executive vice president. This year's annual meeting hit an all-time attendance record. We had over 45,000 people registered, representing 129 countries. Amazing. It really felt very global. All five of the abstracts in the plenary session really will change standard of care, at least when the drugs become available in the US. I think, you know, the overwhelming most impressive big game changer was the RASolute 302 Trial of daraxonrasib, you know, the RAS inhibitor. And it got a standing ovation when the survival curves went up of multiple minutes. You know, probably the biggest advancement in the treatment of cancer in the past decade. So, it was a study in metastatic pancreatic adenocarcinoma patients who had already received one line of therapy in the metastatic setting. The five-year survival rate would be 3% in that setting. There are not good treatments. It was a randomization between daraxonrasib versus an investigator's choice of standard-of-care chemo. The daraxonrasib is a RAS inhibitor, but it's a very cool approach because the problem and the reason we called RAS undruggable was because the way the protein folds, it doesn't have any kind of a deep pocket for a drug to kind of stick in to, very, very shallow pocket. So, with really elegant protein design, this is an oral tricomplex. So, what they took was a chaperone protein, Cyclophilin A; they bound it to RAS and so this, the Cyclophilin A, could attach to RAS kind of right next to where the anti-RAS, the agent, would fit into the pocket and keep it there, right. The primary endpoint was focused on the KRAS G12 population, but that was 90% of the patients. And in that KRAS G12-mutant population, overall survival was 13.2 versus 6.6 months. Progression-free survival 7.3 versus 3.5 months, both strongly statistically significant. And the grade 3, 4 toxicities were less with the daraxonrasib, 43.6% versus 57.5%. There was more rash and more stomatitis. We're going to have to learn how to take care of those. We did hear a little bit in talking to the authors about using topical creams and stuff. Discontinuation related to a treatment-related adverse event was only 1.2% in the daraxonrasib versus 11.2% in the chemo. So, game changer for sure. My name is Sara Tolaney. I'm a breast medical oncologist and chief of the breast oncology program at Dana-Farber Cancer Institute. So, at ASCO this year, we presented results from the ASCENT-04 study. This is a trial that looked at sacituzumab govitecan, a Trop 2-directed antibody drug conjugate, in combination with pembrolizumab compared to chemotherapy plus pembrolizumab in patients who have previously untreated metastatic triple negative breast cancer that is PD-L1+. We've actually previously seen the results from this trial looking at the progression-free survival where we saw that sacituzumab plus pembrolizumab was associated with a significant improvement in progression-free survival compared to chemotherapy plus pembrolizumab. This year, we are presenting biomarker data from the trial, looking at various biomarkers in association with efficacy. In this particular analysis, we looked at a variety of different biomarkers, including Trop 2 expression, which is the target for sacituzumab govitecan. We also looked at BRCA mutation status and looked at HER2 expression and looked for associations with efficacy. What we saw was that patients really benefited from sacituzumab plus pembrolizumab compared to chemotherapy plus pembrolizumab, irrespective of biomarker status. So, for example, for patients when we looked at a Trop 2 expression, we found that sacituzumab plus pembrolizumab did better than chemotherapy plus pembrolizumab, even in the patients with low Trop 2 expression, as well as those patients with high Trop-2 expression. Visit HealthDay.com: https://healthday.com Like HealthDay on Facebook: / healthdaynews Follow HealthDay on Instagram: / healthday_news Follow HealthDay on Twitter: / healthdaytweets Connect with HealthDay on LinkedIn: / 418188 #CancerResearch #Oncology #MedicalBreakthrough #ASCO26 #HealthNews #PancreaticCancer #BreastCancer #TripleNegative #Daraxonrasib #CancerSurvivor
